

MEDI-CAPS LIMITED

Regd. Office and works:

Mhow - Neemuch Road, Sector 1, CIN: L70100MP1983PLC002231
Pithampur - 454775, Dist. Dhar
Madhya Pradesh, India

Ph:- +91-0731-4046321

Fax:- 0731-4041435

E mail:- investors@medicaps.com

Web site:- www.medicaps.com

MCL/SE/2020-2021

Date: 25.07.2020

Online filing at: www.listing.bseindia.com

To,
The General Manager
DCS-CRD
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street Fort, Mumbai – 400001 (M.H.)

BSE Scrip Code: 523144

Subject: Submission of the Standalone and Consolidated Unaudited Financial Results for the Quarter ended on 30th June, 2020 as per Regulation 33(3)(d) of SEBI (LODR) Regulations, 2015.

Dear Sir/Madam,

This is in Continuation of our letter no. MCL/BM/SE/2020-2021 dated 17th July, 2020 regarding submission of Standalone as well as Consolidated Un-Audited Quarterly Financial Results for the Quarter ended on 30th June, 2020.

We are pleased to inform that, Board of Directors at their meeting held on 25th July, 2020 has considered and approved the following which is also being submitted to you:

- (a) Unaudited Standalone and Consolidated Financial Results for the quarter 30th June, 2020; and
- (b) Limited Review Report by the Auditors for the Standalone and Consolidated for the quarter 30th June, 2020.
- (c) Appointment of the Secretarial Auditors of the company as per the provisions of section 204 of the Companies Act, 2013 and rules made there under for financial year 2019-20.

We are also in process of filing the aforesaid financial results in the XBRL format within the stipulated time and the same shall be hosted on the Website of the Company.


The Meeting of the Board of Directors commenced at 3:00 P.M. and concluded at 6:30P.M.


The above results will be published in Hindi (vernacular) and widely circulated English Newspaper.

You are requested to please take on record the aforesaid Unaudited Financial Results along with Limited review Report for your records and reference.

Thanking You,
Yours Faithfully,

For, **MEDI-CAPS LIMITED**


AYUSHI SILOT
COMPANY SECRETARY &
COMPLIANCE OFFICER
M.N. – A54352



- Encl.: 1)-Unaudited Financial Results along with limited review report;
2)- Brief Profile of the Secretarial Auditors of the company.

Corporate Office: 201, Pushpratna Paradise 9/5 New Palasiya,
Opposite UCO Bank, Indore (M.P.) 452001
Contact No: 0731-4028148

MEDI-CAPS LIMITED

Regd. Office and works:

Mhow - Neemuch Road, Sector 1, CIN: L70100MP1983PLC002231
Pithampur - 454775, Dist. Dhar
Madhya Pradesh, India

Ph:- +91-0731-4046321

Fax:- 0731-4041435

E mail:- investors@medicaps.com

Web site:- www.medicaps.com

BRIEF PROFILE OF M/S L.N. JOSHI & CO. (Company Secretaries)

(Appointment of L.N. Joshi & Company, Practicing Company Secretary as Secretarial auditor of the company)

I. Reason for Change:- Due to Resignation of previous Secretarial Auditors.

II. A) Date of Appointment:-25.07.2020


B) Term of Appointment: - financial year 2019-2020

III. Brief Profile:-

Name of Secretarial Auditor	L.N. Joshi & Company, Practicing Company Secretary
PROPRIETOR	L.N. Joshi
QUALIFICATION	M.Com, LLB (Hons), FCS, Insolvency Professional Mr L N JOSHI is Fellow Member of Institute of Companies Secretaries of India . He is post graduate in Commence and also Law Graduate. Apart from this he is also Insolvency Resolution Professional Registered with Insolvency Bankruptcy Board of India. He is in practice since 2001 and having overall experience of more than 19 years in Corporate Laws, RBI, SEBI, Depository Law , Insolvency and Bankruptcy code etc.
INCOME TAX PAN	ADQPJ9566K
MEMBERSHIP NO. CP No.	Membership No.: 5201 CP No.4216
ADDRESS	122, Krishna Business Centre, P U 4 , Medanta Hospital Road, Next To BSNL Building, Indore (M.P.) 452010
E-MAIL ID	lnjoshics@gmail.com


IV. Disclosure of Relationship between Directors:- M/s. L.N. Joshi & Company, Practicing Company Secretary is not having any relationship with any director and company

For, MEDI-CAPS LIMITED


AYUSHI SILOT
COMPANY SECRETARY &
COMPLIANCE OFFICER
M.N. - A54352







Corporate Office: 201, Pushpratna Paradise 9/5 New Palasiya,
Opposite UCO Bank Indore (M.P.) 452001
Contact No: 0731-4028148

**LIMITED REVIEW REPORT ON UNAUDITED STANDALONE
QUARTERLY FINANCIAL RESULTS OF MEDI-CAPS LIMITED**

To,
THE BOARD OF DIRECTORS OF
MEDI-CAPS LIMITED


1. We have reviewed the accompanying Unaudited Standalone Financial Results of **MEDI-CAPS LIMITED** ("the Company"), for the Quarter ended June 30, 2020 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (LODR) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.


This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 Interim financial reporting "IND AS 34" prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the statement based on our review.

2. We conducted our review of the statement in accordance with the Standard on review engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (LODR) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.
4. On 21st Nov., 2020, the company announced to permanently discontinue Company's operations related to production/manufacturing of Hard Gelatin Capsule Shell in the plant situated at Mhow - Neemuch Road, Sector 1, Pithampur - 454775, Distt. Dhar. The discontinuation is consistent with the Company's long-term strategy to focus its activities in the areas of Real Estate Business and to divest unrelated activities. Accordingly, Loss for the quarter ended June 30, 2020 is from discontinuing operation.

Place: Indore
Date: 25/07/2020
UDIN: 20429040AAAABQ9917

For: Rawka & Associates
(Chartered Accountants)




Venus Rawka
(Partner)
M. No. 429040
FRN: 021606C

Independent Auditor's Review Report On consolidated unaudited quarterly and year to date financial results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

**TO THE BOARD OF DIRECTORS OF
Medi-Caps Limited**

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **Medi-Caps Limited** and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit/(loss) after tax and total comprehensive income / loss of its subsidiary for the quarter ended 30/06/2020 and for the period from 01/04/2020 to 30/06/2020, being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. Attention is drawn to the fact that the consolidated figures for the corresponding quarter ended 30/06/2019 and the corresponding period from 01/04/2019 to 30/06/2019, as reported in these financial results have been approved by the Parent's Board of Directors.

2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of its subsidiary Medgel Private Limited.


5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consolidated review report of its subsidiary, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. Our conclusion is not modified in respect of this matter.


7. The consolidated unaudited financial results includes the interim financial statements/ financial information/ financial results of Medgel Private Limited (subsidiary) which have not been reviewed/audited by their auditors, whose interim consolidated financial statements/ financial information/ financial results reflect total revenue of Rs. ~~1248.03~~ Lakhs, total net profit/(loss) after tax of Rs. ~~238.17~~ Lakhs and total comprehensive income of Rs. 73.10 Lakhs for the quarter ended 30/06/2020, as considered in the consolidated unaudited financial results. According to the information and explanations given to us by the Management, these interim financial statements / financial information / financial results are not material to the Group.

Our conclusion on the Statement is not modified in respect of the above matter

Place: Indore
Date: 25/07/2020
UDIN: 20429040AAAABR6163



For: Rawka & Associates
Chartered Accountants


Venus Rawka
(Partner)
M.No. 429040
FRN: 021606C

MEDI-CAPS LIMITED

REGD. OFFICE: MHOW-NEEMUCH ROAD, SECTOR-1, PITHAMPUR-454775, DISTT. DHAR (M.P.), Tel: 07292-424242, Fax: 07292-407387


Website: www.medicaps.com Email: investors@medicaps.com CIN: L24232MP1983PLC002231

STANDALONE AND CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2020

PART I

Sr. No.	Particulars	Standalone				Consolidated			
		3 Months ended on		Year Ended		3 Months ended on		Year Ended	
		30.06.2020 (Unaudited)	31.03.2020 (Audited)	30.06.2019 (Unaudited)	31.03.2020 (Audited)	30.06.2020 (Unaudited)	31.03.2020 (Audited)	30.06.2019 (Unaudited)	31.03.2020 (Audited)
I	Income from operations								
	(a) Net sales	0.00	73.03	462.92	1090.85	1202.82	590.90	1577.90	4305.20
	(b) Other operating income	0.00	17.34	20.24	56.59	17.01	188.24	20.24	227.49
	Total Income from operations	0.00	90.37	483.15	1147.44	1219.83	779.14	1598.14	4532.70
II	Other Income	0.00	16.38	0.00	55.15	28.20	70.14	17.33	59.53
III	Total income (I+II)	0.00	106.75	483.15	1202.59	1248.03	849.28	1615.47	4592.23
IV	Expenses								
	a) Cost of material consumed	0.00	19.00	200.29	541.03	549.70	304.67	900.60	2232.80
	b) Purchase of stock in trade	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	c) Changes in Inventories of finished goods, & work in progress	0.00	20.45	(4.54)	452.75	23.26	54.42	16.66	449.65
	d) Employee benefits expense	0.00	52.37	127.15	588.21	132.87	212.76	240.49	1103.77
	e) Finance Cost	0.00	0.17	0.26	0.86	0.00	0.18	0.31	1.69
	f) Power Cost	0.00	0.34	81.16	194.67	50.97	55.78	113.02	374.76
	g) Depreciation expense	0.00	8.36	9.06	35.54	37.31	44.76	45.83	183.01
	h) Other expenses	0.00	18.70	63.42	221.36	215.75	271.48	232.69	830.90
	Total Expenses (IV)	0.00	119.39	476.79	2034.42	1009.86	944.05	1549.60	5176.58
V	Profit/(Loss) before exceptional items and tax (III-IV)	0.00	-12.64	6.37	-831.83	238.17	-94.76	65.87	-584.35
VI	Exceptional items	0	0	0	0	0	0	0	0
VII	Profit/(Loss) before tax	0.00	-12.64	6.37	-831.83	238.17	-94.76	65.87	(584.35)
VIII	Tax expense								
	a) Current Tax	0.00	0.00	2.00	0.00	0.00	0.00	2.00	0.00
	b) Deferred Tax	0.00	0.84	0	0.84	0.00	-0.80	0.00	0.84
	Total Tax Expenses	0.00	0.84	2.00	0.84	0.00	-0.80	2.00	0.84
IX	Profit (+)/Loss (-) for the period from continuing operations (VII-VIII)	0.00	-13.48	4.37	-832.67	238.17	-93.96	63.87	-585.19
X	Profit / (Loss) from Discontinuing operations	-27.45	0.00	0.00	0.00	-27.45	0.00	0.00	0.00
XI	Tax expenses from Discontinuing operations	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
XII	Profit / (Loss) from Discontinuing operations (after tax (X-XI))	-27.45	0.00	0.00	0.00	-27.45	0.00	0.00	0.00
XIII	Profit / (Loss) for the period (IX+XII)	-27.45	-13.48	4.37	-832.67	210.72	-93.96	63.87	-585.19
XIV	Other Comprehensive Income:								
	A (i) Items that will not be reclassified to Profit or Loss	33.17	-38.58	101.71	66.41	73.10	-18.02	135.56	120.30
	(ii) Income Tax relating to items that will not be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	B (i) Items that will be re-classified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income Tax relating to items that will be reclassified to Profit or loss	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Other Comprehensive Income:	33.17	(38.58)	101.71	66.41	73.10	(18.02)	135.56	120.30
XV	Total Comprehensive Income for the period (XIII + XIV) (Comprising profit/(Loss) & other comprehensive income for the period)	5.72	-52.06	106.08	-766.26	283.82	-111.98	199.43	-464.89
XVI	Paid up Equity Share Capital (F.V. of Rs. 10/- each)	1247.00	1247.00	1247.00	1247.00	1247.00	1247.00	1247.00	1247.00
XVII	Reserve and Surplus (Excluding Revaluation Reserve)	-	-	-	4737.52	-	-	-	7848.45
XVIII	Earnings Per Share (for continuing operations)								
	(a) Basic	0.05	-0.42	0.85	-6.14	2.28	-0.90	1.60	-3.73
	(b) Diluted	0.05	-0.42	0.85	-6.14	2.28	-0.90	1.60	-3.73
XIX	Earnings Per Share (for discontinued operations)								
	(a) Basic	0.00	0.00	0.00	0.00	0.05	0.00	0.00	0.00
	(b) Diluted	0.00	0.00	0.00	0.00	0.05	0.00	0.00	0.00
XX	Earnings Per Share (for Discontinued and continuing operations)								
	(a) Basic	0.05	-0.42	0.85	-6.14	2.32	-0.90	1.60	-3.73
	(b) Diluted	0.05	-0.42	0.85	-6.14	2.32	-0.90	1.60	-3.73

Notes:



1. The above unaudited financial results for the Quarter ended June 30, 2020 were reviewed and recommended by the Audit Committee and approved by the Board of Directors in its meeting held on 25th July, 2020. The above results have been reviewed by statutory Auditors of the company in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Company's Management has exercised necessary due diligence to ensure that the financial results provide a true and fair view of its affairs
2. The above consolidated financial statement includes the financial figures of wholly owned subsidiary Company i.e. MEDGEL PRIVATE LIMITED
3. The company is operating in one segment. Further, in the AGM held on 25th Sept., 2019 the company altered the Clause III (A) of the Memorandum of Association of Company by insertion of the new Clause 2.1 after the existing Clause III (A) 2 and the company has entered into Real Estate Business for which the company has applied for various licenses and approval from various government departments but due to outbreak of a pandemic all the necessary approvals are pending from various Govt. departments due to which the project will be delayed and there is no income/expenditure of the same.
4. Effective from 1st April, 2019, the company has adopted Indian Accounting Standards (IND AS) 116 "leases" using the "Modified Prospective Approach". The adoption of the said IND AS did not have any impact on the retained earnings as at 1st April, 2019 and there was no material impact on financial results for the quarter ended on 30th June, 2020.
5. Previous period figures have been regrouped /reclassified wherever necessary to confirm to this period classification
6. The aforesaid unaudited financial results will be uploaded on the Company's website www.medicaps.com and will also be available on the website of the BSE Limited www.bseindia.com for the benefit of shareholders and investors
7. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable
8. On 21st Nov., 2019, the company announced to permanently discontinue Company's operations related to production/manufacturing of Hard Gelatin Capsule Shell. The discontinuation is consistent with the Company's long-term strategy to focus its activities in the areas of Real Estate Business and to divest unrelated activities. Accordingly, Loss for the quarter ended June 30, 2020 is from discontinuing operation.

9. Description of Income & Expenditure of Discontinue Operation

Particulars	Amt.(In Lakhs)
I Income from operations	0
II Other Income	10.64
III Total Income (I+II)	10.64
IV Expenses	
Changes in Inventories of finished goods, & work-in progress	0.53
Employee benefits expense	4.63
Finance Cost	0.13
Depreciation expense	9.06
Other expenses	23.74
Total Expenses (IV)	38.09
Net Loss From Discontinue Operation	-27.45

10. Company from discontinued operations generated income of Rs 10.64 lacs and incurred expenses of Rs 38.09 lacs resulting into net loss of Rs 27.45 lacs.

Place : INDORE
Date : 25/07/2020

For, MEDICAPS LIMITED


ALOK K GARG
MANAGING DIRECTOR
DIN: 00274321

